Trevi's Haduvio: A New Hope for Millions with Intractable Chronic Cough?

NEW HAVEN, CT – March 02, 2026 – As Trevi Therapeutics prepares its senior leadership for a series of high-profile presentations at healthcare conferences this March, the biopharmaceutical world is watching with keen interest. The company is not just showcasing its financials; it's highlighting a potential lifeline for millions suffering from severe, unrelenting chronic cough. At the center of this attention is Haduvio, an investigational therapy that has shown unprecedented success in clinical trials, offering a glimmer of hope where none has existed.

For patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), the simple act of breathing is a constant battle. The accompanying cough is not a mere annoyance but a debilitating, life-altering condition. Trevi’s upcoming participation in the Leerink Partners Global Healthcare Conference and the Access USA Rare Disease Summit is more than a corporate calendar entry; it’s a strategic move to spotlight a drug that could fundamentally change the treatment paradigm for these devastating conditions.

The Crushing Burden of a Never-Ending Cough

To understand the significance of Trevi's work, one must first grasp the profound suffering caused by these conditions. There are currently no FDA-approved therapies for the chronic cough associated with IPF, non-IPF ILD, or RCC. This leaves a vast and desperate patient population in a therapeutic void.

Consider the numbers: an estimated 2-3 million people in the U.S. suffer from RCC, a persistent cough lasting more than eight weeks that defies treatment for any underlying cause. For patients with IPF, a progressive and fatal lung disease, the situation is equally grim. Up to 85% of the approximately 150,000 IPF patients in the U.S. endure a chronic cough, with some coughing up to 1,500 times a day. This constant, violent coughing can worsen the underlying disease, increase the risk of hospitalizations, and shatter a person's quality of life, impacting sleep, work, and social interaction.

"The psychosocial impact is often the largest factor affecting quality of life," noted one pulmonary disease expert. Patients report anxiety, depression, and social isolation, avoiding public spaces for fear of disruptive coughing fits. This is the harsh reality that Trevi Therapeutics aims to address.

A Scientific Breakthrough in Cough Suppression

Haduvio (oral nalbuphine ER) is not just another cough treatment. Its unique mechanism sets it apart. It is a kappa agonist and mu antagonist (KAMA), meaning it works on opioid receptors both centrally in the brain's cough center and peripherally in the lungs. This dual-action approach targets the cough reflex arc in a way that other investigational drugs have not.

The clinical data speaks for itself. In the Phase 2b CORAL trial for IPF-related chronic cough, Haduvio demonstrated a statistically significant reduction in 24-hour cough frequency across all dose levels compared to a placebo. At the highest dose, patients saw a 43.3% greater reduction in coughs than the placebo group, with benefits appearing in as little as two weeks. Critically, up to 65% of patients on Haduvio achieved at least a 50% reduction in coughs, a life-changing metric for those afflicted.

The results from the Phase 2a RIVER trial in refractory chronic cough were even more striking. Patients experienced a staggering 67% reduction in 24-hour cough frequency from baseline, which translated to a 57% placebo-adjusted reduction. The effect was consistent across patients with moderate and severe cough, and 84% of those on Haduvio saw at least a 30% reduction in coughs, compared to just 29% on placebo.

Navigating a Challenging Competitive Landscape

The path to FDA approval for a chronic cough drug is notoriously difficult. The market is littered with therapies that have shown initial promise only to falter in late-stage trials or at the regulatory finish line. Merck & Co.'s P2X3 antagonist, Gefapixant, serves as a cautionary tale. Despite being approved in Europe and Japan, it has received two complete response letters from the FDA, citing insufficient evidence of effectiveness for the U.S. market.

This challenging environment is precisely why Haduvio’s robust and consistent data is turning heads. By demonstrating significant efficacy in two distinct and hard-to-treat patient populations (IPF and RCC), Trevi has positioned its candidate as a potential standout. The company’s leadership has emphasized that Haduvio’s dual KAMA mechanism may be the key to its success, distinguishing it from peripherally acting agents that have shown more limited or inconsistent results.

A Foundation of Financial Strength and Strategic Vision

Developing a breakthrough drug requires more than just good science; it demands immense capital and a sound strategy. Trevi Therapeutics appears to be well-fortified on both fronts. The company ended the third quarter of 2025 with $194.9 million in cash and marketable securities, a war chest it projects will fund operations through 2028. This strong financial footing, bolstered by a $115 million fundraising round in June 2025, provides a long runway to advance Haduvio through its pivotal late-stage trials.

This financial health is mirrored by strong confidence from the investment community. A consensus of eleven analysts has rated Trevi's stock a "Strong Buy," with an average price target suggesting significant upside. The upcoming conference appearances are a key part of the strategy to maintain this momentum, keeping the company and its compelling clinical story in front of key investors and partners.

Trevi is moving swiftly on its development plan. Following a planned End-of-Phase 2 meeting with the FDA in the first quarter of 2026, the company intends to initiate a Phase 3 program for IPF chronic cough and a Phase 2b trial for RCC in the first half of the year.

The Unspoken Advantage: A Non-Scheduled Opioid

Perhaps one of Haduvio's most significant commercial advantages lies in a subtle regulatory detail: its active ingredient, nalbuphine, is not a scheduled substance by the U.S. Drug Enforcement Agency (DEA). While nalbuphine is a synthetic opioid, its mixed-action properties—blocking the mu receptor associated with euphoria and addiction while activating the kappa receptor for therapeutic effect—have historically given it a low profile for abuse.

This non-scheduled status could be a game-changer in the marketplace. It would free Haduvio from the stringent prescribing, tracking, and administrative burdens placed on controlled substances. Physicians may be more willing to prescribe it, and patients may face fewer hurdles in accessing it. In an era rightly defined by caution around opioid use, a therapy that can offer opioid-like efficacy without the same regulatory baggage represents a powerful proposition.

With pivotal trials on the horizon, the path forward for Haduvio will be closely watched by patients, physicians, and investors alike. For the millions who have waited years for a reprieve from a relentless cough, the next steps cannot come soon enough.